Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth in 2025?
Recent years have seen a robust growth in the market for nucleic acid and gene therapies in neuromuscular disorders. The market, currently valued at $6.84 billion in 2024, is poised to hit $7.52 billion in 2025, marking a compound annual growth rate (CAGR) of 9.9%. The growth witnessed in the past is largely due to increases in regulatory approvals, a higher demand for nucleic acid-based therapies, a call for more precise and effective treatment methods, a surge in the demand for efficient gene therapies, and a rise in the discoveries related to gene therapy.
What Is the Forecast for the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Size Through 2029?
The market size for nucleic acid and gene therapies within neuromuscular disorders is predicted to exhibit considerable growth in the upcoming years, reaching $10.87 billion in 2029 with a compound annual growth rate (CAGR) of 9.7%. Market growth during the forecast period is set to be driven by factors such as the rising occurrence of genetic disorders, increased investment in research and development, heightened demand for precision medicine, a surge in approval for gene therapy products, and a growing rate of chronic disorders. Key trends shaping the forecast period include advancements in patient care, high-performing chromatography, innovative treatments for ailments, the evolution of gene editing technologies, and the availability of technologies for nucleic acid extraction.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21233&type=smp
What are the Key Market Players in Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market and How They’re Evolving?
Major companies operating in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Généthon S.A, Axovant Gene Therapies Inc.
What Are the Primary Growth Drivers in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
The surge in genetic disorders is anticipated to stimulate advances in the nucleic acid and gene therapies domain for neuromuscular ailments. These disorders, resulting from DNA malformations inherited or emerging from mutations, are on an uptick because of factors such as genetic transformations, environmental factors, lifestyle alterations, and advancements in diagnostic procedures. Nucleic acid and gene therapies contribute to genetic disorders by rectifying or substituting defective genes in neuromuscular situations to regain correct functioning. For instance, data from Cure SMA, an American non-profit organization, revealed that as of May 2024, around 9,000 to 9,500 individuals in the United States are living with Spinal Muscular Atrophy (SMA). Among them, 37% are diagnosed with Type 2 SMA. The disorder’s projected incidence rate is 1 in 15,000 births. Hence, the escalating prevalence of genetic disorders bolsters the growth of the nucleic acid and gene therapies in the market for neuromuscular disorders.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21233&type=smp
What Are the Leading Segments in the Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Industry?
The nucleic acid and gene therapies in neuromuscular disorders market covered in this report is segmented –
1) By Disorder: Motor Neuron Diseases, Neuropathies, Neuromuscular Junction Disorders, Myopathies Including Muscular Dystrophies
2) By Therapy: Adeno-Associated Viruses Gene Therapy, Postnatal Gene Therapy, Spinal Muscular Atrophy
3) By Application: Hospitals, Specialty Clinics, Ambulatory Surgery Centers
Subsegments:
1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis (PLS)
2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT), Hereditary Sensory and Autonomic Neuropathy (HSAN), Peripheral Neuropathies
3) By Neuromuscular Junction Disorders: Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome (LEMS)
4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb-Girdle Muscular Dystrophy (LGMD), Facioscapulohumeral Muscular Dystrophy (FSHD)
What Are the Key Market Trends in the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Industry?
Leading organizations are currently involved in the market for nucleic acid and gene therapies for neuromuscular disorders, aiming to develop groundbreaking therapies such as gene therapy. This approach targets the origin of genetic neuromuscular conditions by rectifying or replacing the relevant genes. Gene therapy is a technique of treating diseases by modifying, amending, or restoring genetic material in a patient’s cells in order to correct or replace abnormal genes. For instance, Sarepta Therapeutics Inc., a biotechnology firm based in the U.S., achieved approval from the U.S. Food and Drug Administration in June 2023 for Elevidys – the initial gene therapy for Duchenne Muscular Dystrophy. The therapy targets ambulatory pediatric patients aged from 4 to 5 years and simplifies the treatment technique compared to other therapies that may necessitate regular infusions. ELEVIDYS introduces a gene that signifies a shortened version of dystrophin, which is critical for muscle function. This novel method rectifies the root genetic flaw, allowing muscle cells to generate a functional version of the dystrophin protein, potentially halting or even reversing the progress of the disease.
Access The Full Report Here:
What Is the Regional Outlook for the Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market?
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21233
This Report Delivers Insight On:
1. How big is the nucleic acid and gene therapies in neuromuscular disorders market, and how is it changing globally?
2. Who are the major companies in the nucleic acid and gene therapies in neuromuscular disorders market, and how are they performing?
3. What are the key opportunities and risks in the nucleic acid and gene therapies in neuromuscular disorders market right now?
4. Which products or customer segments are growing the most in the nucleic acid and gene therapies in neuromuscular disorders market?
5. What factors are helping or slowing down the growth of the nucleic acid and gene therapies in neuromuscular disorders market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model